Oct 14, 2019 7:00am EDT Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis
Oct 07, 2019 7:00am EDT Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis
Sep 25, 2019 7:00am EDT Matinas BioPharma Announces Pre-Screening of Patients to Determine Eligibility for Phase 2 ENHANCE-IT Study Against Vascepa®
Aug 28, 2019 7:30am EDT Matinas BioPharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Aug 13, 2019 6:45am EDT Matinas BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 30, 2019 7:30am EDT Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2019 Operational and Financial Results on August 13, 2019
Jul 25, 2019 7:30am EDT Matinas BioPharma Receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis
May 28, 2019 8:00am EDT Matinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio
